Studies show that vaccines against COVID gives additional protection to infected persons

The drugs have proved very effective in protecting those who have never had COVID, but their effectiveness in preventing symptoms and severe results in people who were infected before has until recently been less obvious.

Now two separate parts of the research, published in Lancet Infectious Diseases magazine, confirm that vaccines against COVID-19 provides additional protection to people who have already been infected with Sars- CoV-2 specifically against serious illness.

In the first study, conducted in Brazil, researchers found that four vaccines é CoronaVac, Oxford/AstraZeneca, Janssen and Pfizer/ B NTech ʹ offer additional protection against symptoms reinfluence and severe results such as hospitalization and death on people who had previously been infected with coronarys.

The second study, from Sweden, found that the vaccine against Ovid 19 offered additional protection to those who had received COVID earlier for at least nine months.

Together, studies provide essential information on the effectiveness of the vaccine in people with a previous infection and underline the benefits of the vaccine, regardless of whether one has had COVID. Experts say the findings could also help inform global vaccine strategies.

In the first study, which included more than 22,000 people with COVID, the data showed that vaccination reduces the risk of symptoms, hospitalization, or death.

The second study, involving almost 3 million people, found that a dose of vaccines in someone with infection-led immunity from a previous infection reduced the risk of reinfluence by 58% two months after management. Two doses of the vaccine reduced the risk of infection by 66%.

The authors accepted restrictions with both studies, including the risk of prejudice due to the observer nature of research. Furthermore, no study included a reinfluence analysis from Omitron variants.